Lipigon Pharmaceuticals AB Total Liabilities

Latest as of December 2025: Skr3.57 Million SEK ≈ $384.51K USD

Lipigon Pharmaceuticals AB total liabilities. Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has total liabilities worth Skr3.57 Million SEK (≈ $384.51K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lipigon Pharmaceuticals AB (LPGO) asset resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Lipigon Pharmaceuticals AB (2017–2025)

Total liabilities of Lipigon Pharmaceuticals AB from 2017 to 2025. This chart illustrates how Lipigon Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data.

Lipigon Pharmaceuticals AB Competitors by Total Liabilities

The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their total liabilities.

Company	Country	Total Liabilities
Block Energy PLC LSE:BLOE	UK	GBX3.37 Million
OCA Acquisition Corp NASDAQ:OCAXU	USA	$15.99 Million
Predator Oil & Gas Holdings Plc LSE:PRD	UK	GBX10.58 Million
Sancus Lending Group Ltd LSE:LEND	UK	GBX193.93 Million
Livento Group Inc. NASDAQ:NUGND	USA	$2.80 Million
AYURCANN HOLDINGS CORP. F:3ZQ0	Germany	€15.44 Million
Advanced Info Service Public Company Limited F:AISF	Germany	€312.99 Billion
ARWAY CORP. F:E65	Germany	€1.02 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Lipigon Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Lipigon Pharmaceuticals AB's balance sheet.

Liquidity & Leverage Metrics

Lipigon Pharmaceuticals AB Total Liabilities Ratios Explained

Lipigon Pharmaceuticals AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.14	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.45	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lipigon Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lipigon Pharmaceuticals AB (2017–2025)

The table below shows the annual total liabilities of Lipigon Pharmaceuticals AB from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr3.57 Million ≈ $384.51K	-49.41%
2024-12-31	Skr7.06 Million ≈ $759.98K	+36.91%
2023-12-31	Skr5.16 Million ≈ $555.08K	-25.73%
2022-12-31	Skr6.95 Million ≈ $747.39K	+7.41%
2021-12-31	Skr6.47 Million ≈ $695.84K	+186.23%
2020-12-31	Skr2.26 Million ≈ $243.10K	+117.00%
2019-12-31	Skr1.04 Million ≈ $112.03K	-2.44%
2018-12-31	Skr1.07 Million ≈ $114.83K	-99.83%
2017-12-31	Skr619.85 Million ≈ $66.71 Million	--

About Lipigon Pharmaceuticals AB

ST:LPGO Sweden Biotechnology

Market Cap

$97.81K

Skr908.90K SEK

Market Cap Rank

#31534 Global

#747 in Sweden

Share Price

Skr0.00

Change (1 day)

-44.44%

52-Week Range

Skr0.00 - Skr0.11

All Time High

Skr10.15